Category

General
Courtney is a Trial Manager in the Stress, Psychiatry and Immunology (SPI) Lab at the IOPPN, Kings College London. What drew you to psychiatric research? I grew up in a time where the importance of mental health was on the raise. Besides, I had a genuine desire to help people. And what better way to...
Read More
Creating a collaborative environment integrated by a diversity of stakeholders is vital to move forward on the innovative paradigm of Integrated Research Platforms (IRPs). Next October, experts from health authorities, ethic committees, patient organizations, health technology assessments, industry/pharmaceutical companies and academic investigators/hospital networks involved in drug development are called to attend EU-PEARL’s first Stakeholder Workshop...
Read More
Around 300 Consortium members are called to attend EU-PEARL second General Assembly Meeting (GAM) organised along four half-day sessions during September and October. All sessions will take place online due to the restrictions imposed by COVID-19. Besides, representing an excellent opportunity to keep the full Consortium abreast of the latest developments in the project, this...
Read More
I work as a marketing and sales director for a large hospitality company and have moved countries often. As the daughter of a French diplomat, I spent many years abroad -I was born in New Caledonia- and later in life, I settled temporarily in Costa Rica, where both my kids where born. There, we enjoyed...
Read More
EU-PEARL is taking further steps to ensure that patients will be at the centre in the new paradigm of clinical trials. So, in the upcoming weeks the Patient Advisory Board (PAG) will take off, whilst a session scheduled for the project’s General Assembly Meeting (GAM) will be devoted to patient engagement. In May, EU PEARL...
Read More
The domain of EU-PEARL’s research, Integrated Research Platforms (IRPs) and platform trials is relatively new and consequently the vocabulary is still work in progress.  Hence, the need to develop a common understanding and usage of terminology beyond EU-PEARL. With this goal in mind, D2.1. Report on Terminology, References and Scenarios for Platform Trials and Master...
Read More
As the biomedical sector rapidly mobilizes to address the novel coronavirus pandemic, we are encouraged to see the strong embrace of collaboration, master protocols and platform studies, all in the spirit of delivering the most useful information in the fastest way possible to save lives. The most prominent example is the launch of the adaptive...
Read More
Patient centricity is at the core of EU-PEARL’s mission. That is why we are engaging with patients from the start to co-design the platform trial framework, thus bringing on board more patient-relevant outcomes. Making clinical trials more efficient and patient friendly can ensure that individuals find the clinical trial that matches their needs, that companies...
Read More
Physician, specialised in internal medicine, infectious diseases and epidemiology/public health. EU-PEARL’s scientific co-coordinator, giving support to Dr Joan Genescà. He is part of the VHIR team. – How and why did you become involved in EU-PEARL? I have been passionately engaged in research ever since the early stages of my career combining my work as...
Read More
EU-PEARL will participate in the Children’s Tumor Foundation (CTF) Annual Conference which will take place online next June 15th and 16th. This global forum focuses on building consensus and advancing translational and clinical research to improve outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. Every year, this event attracts nearly 500...
Read More
1 2

Signup to stay informed